Cost Calculator of Immunotherapies in 1L Endometrial Cancer Treatment for the Deficient Mismatch Repair, Proficient Mismatch Repair, and Intention-to-Treat Populations From the Brazilian Private Healthcare System
Author(s)
Marcella de Alemar, BSc, Graziela Bernardino, MBA, Fabiana Reis, PhD, Danielle Silva, MSc, Straus Tanaka, PharmD.
GSK, São Paulo, Brazil.
GSK, São Paulo, Brazil.
OBJECTIVES: The aim of this study was to evaluate the cost of adoption of recently approved immunotherapies for the first-line (1L) treatment of advanced or recurrent endometrial cancer (EC) for the intention-to-treat (ITT), deficient mismatch repair (dMMR), and proficient mismatch repair (pMMR) populations over the first 3 years of treatment.
METHODS: A cost calculator was developed to estimate the treatment costs of dostarlimab, pembrolizumab, durvalumab, and durvalumab + olaparib for EC. A scenario of 10 new patients per year for each treatment was considered. In the first year, 10 patients were included; from the second year onwards, the prevalence of patients from the previous year was added to the 10 new patients of the current year. Progression-free survival curve data from the RUBY trial (NCT03981796) were used as an assumption for treatment duration for the therapies. Treatment costs considered drug prices from May 2025 of the official Brazilian list price by the Chamber of Regulation of the Pharmaceutical Market. Only immunotherapies costs were considered.
RESULTS: Total 3-year costs for ITT: dostarlimab R$19,947,786, pembrolizumab R$22,317,641, and durvalumab R$22,610,468. For dMMR: dostarlimab R$24,810,040, pembrolizumab R$25,798,868, and durvalumab R$28,719,729. For pMMR: dostarlimab R$18,593,552, pembrolizumab R$21,248,054, durvalumab R$21,038,932, and durvalumab + olaparib R$31,633,298.
CONCLUSIONS: Dostarlimab presented the lowest treatment cost among the immunotherapy options in 1L for EC irrespective of mutation status, which may lead to better budget allocation and access to the novel therapy.
METHODS: A cost calculator was developed to estimate the treatment costs of dostarlimab, pembrolizumab, durvalumab, and durvalumab + olaparib for EC. A scenario of 10 new patients per year for each treatment was considered. In the first year, 10 patients were included; from the second year onwards, the prevalence of patients from the previous year was added to the 10 new patients of the current year. Progression-free survival curve data from the RUBY trial (NCT03981796) were used as an assumption for treatment duration for the therapies. Treatment costs considered drug prices from May 2025 of the official Brazilian list price by the Chamber of Regulation of the Pharmaceutical Market. Only immunotherapies costs were considered.
RESULTS: Total 3-year costs for ITT: dostarlimab R$19,947,786, pembrolizumab R$22,317,641, and durvalumab R$22,610,468. For dMMR: dostarlimab R$24,810,040, pembrolizumab R$25,798,868, and durvalumab R$28,719,729. For pMMR: dostarlimab R$18,593,552, pembrolizumab R$21,248,054, durvalumab R$21,038,932, and durvalumab + olaparib R$31,633,298.
CONCLUSIONS: Dostarlimab presented the lowest treatment cost among the immunotherapy options in 1L for EC irrespective of mutation status, which may lead to better budget allocation and access to the novel therapy.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE158
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology